Patients
HFpEF, HF
ATRIAL FIBRILLATION, HEART
EMPA-VISION comprised 2 separate cohorts with HFrEF (left ventricular ejection fraction [LVEF] ≤40%) and HFpEF (LVEF ≥50%). Trial patients were considered eligible with an established diagnosis of nonischemic, chronic HF with typical signs (NT-proBNP [N-terminal pro-B-type natriuretic peptide] >125 pg/mL in sinus rhythm or >600 pg/mL in atrial fibrillation) and symptoms (New York Heart Association classes II–IV) and appropriate doses of guideline-directed HF medical therapy. In addition, patients with HFpEF were required to display significant signs of adverse structural remodeling (left atrial volume index >34 mL/m